Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lab21 and IntegraGen Partner to Develop New Colorectal Cancer Diagnostic

Published: Tuesday, February 26, 2013
Last Updated: Monday, February 25, 2013
Bookmark and Share
Lab21 to develop a CE marked assay to detect expression levels of a microRNA biomarker.

Lab21 Limited has entered into an agreement with IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in autism and oncology, to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.

Under the agreement, Lab21 will develop a CE marked assay, using its proprietary SPARQ™ PCR technology, to detect expression levels of a microRNA biomarker called hsa-mir-31-3p, which was discovered and patented by IntegraGen and its academic partners.

Early research with this biomarker has shown that it may predict response to EGFR inhibitor therapy in KRAS-wild type patients who have metastatic colorectal cancer. Financial details were not disclosed.

Most patients with metastatic colorectal cancer are currently screened and stratified by determining mutations in the KRAS gene.

Approximately 40% of these patients carry a KRAS mutation and are not candidates for EGFR inhibitor therapy.

Of the approximately 60% of patients who do not carry a KRAS mutation (i.e. KRAS wild type) and who are eligible for EGFR inhibitor therapy, effectiveness is still only 50-60%.

MicroRNA expression testing may provide a further level of stratification and thus aid clinicians to identify KRAS wild type patients most likely to respond to treatment: improving outcomes, avoiding adverse reaction and saving money in the healthcare system.

Graham Mullis, CEO of Lab21, commented: “We are delighted to enter into this assay development agreement with IntegraGen. Lab21’s experience in developing molecular diagnostics in the oncology and infectious disease settings is increasingly being recognized by major diagnostic manufacturers and pharmaceutical partners. The combination of our highly efficient assay development capability, regulatory and manufacturing know-how is actively being sought by developers of novel diagnostics, such as IntegraGen, who need partners to commercialize their biomarkers, including a route to market.”

Bernard Courtieu, CEO of IntegraGen, added: “We are pleased to be working with Lab21 to progress this biomarker towards commercialization in Europe. On the basis of good clinical results and regulatory approval we hope to have a CE Marked kit available based on Lab21’s technology by early 2014. With over 500,000 patients diagnosed with metastatic colorectal cancer annually on a global basis, there is a large market potential for an assay based on this biomarker.”

Following development of the assay, Lab21 and IntegraGen will explore other opportunities for partnerships relative to the manufacturing and commercialization of this novel oncology biomarker.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novacyt, Lab21 to Combine in Stock-For-Stock Transaction
On completing the transaction, Lab21 will become a 100% subsidiary of Novacyt, and the combined group will be rebranded.
Wednesday, May 28, 2014
Lab21, Quidel Expand International Distribution Agreement
Expanded agreement will see Lab21 distribute AnDiaTec’s Real-Time PCR Tests within the UK.
Tuesday, February 11, 2014
Lab21 Announces Sale of South Carolina Operations
Company announces sale of its laboratory operations to Reedy Acquisitions Corp.
Tuesday, April 23, 2013
Lab21 and IntegraGen Partner
Lab21 Limited has entered into an agreement with IntegraGen to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.
Tuesday, March 05, 2013
BD and Lab21 Collaborate
Both Companies collaborate to develop new oncology assays on the BD MAX™ platform.
Tuesday, October 16, 2012
Clydesdale Bank £5 Million Funding to Support Lab21 International Growth
Lab21 is expected to deliver greater than 30% revenue growth in 2012.
Tuesday, July 10, 2012
Lab21 Partners with Major Pharmaceutical Company to Develop New Companion Diagnostic Assay
Agreement allows Lab21 to develop, manufacture and distribute a new companion diagnostic assay for the detection of specific mutations in colorectal cancer samples to select patients for the partner's therapeutic monoclonal antibody.
Tuesday, June 26, 2012
Lab21 Secures European and USA Patents for HCV Drug Resistance Genotyping
Company to expand its intellectual property portfolio in infectious disease testing.
Monday, May 21, 2012
Lab21 Unveils New Molecular Analysis Services at Greenville Site
The first assays in the test menu include a new Human Papillomavirus (HPV) High Risk and HPV 16 and 18 Genotyping Service.
Monday, May 14, 2012
Lab21 and ITOR Launch Clinical Genomics Center in USA
New Clinical Genomics Center will be located within the Greenville Hospital System (GHS) Memorial Medical Campus in Greenville, South Carolina.
Wednesday, March 07, 2012
Lab21 Acquires New Real Time PCR Technology
Company announces the completion of a worldwide license from Cooperative Diagnostics to use its suite of patents and expertise for the development of its growing pipeline of molecular diagnostic kits.
Monday, February 27, 2012
Lab21 Acquires New Real Time PCR Technology
Company expects to launch diagnostic assays using PCR technology during first half of 2012.
Wednesday, January 25, 2012
Lab21 Acquires Molecular Diagnostics Company Myconostica
The acquisition of Myconostica expands Lab21’s growing proprietary diagnostic portfolio and will provide the Company’s first set of nucleic acid-based assays.
Tuesday, May 24, 2011
Lab21 Secures new Patents in Hepatitis C Drug Resistance and Fluorescent Carbon-Based Nanoparticle Technology
New patent refers to technology allowing the genotypic identification of drug resistant mutations in the 4 major global genotypes of HCV.
Thursday, December 09, 2010
Lab21 to Support New US Cancer Institute With Molecular Diagnostic and Clinical Trial Services
Lab21 announces an agreement with ITOR to provide molecular diagnostic support services for new initiatives in drug development and advanced cancer patient care.
Wednesday, October 20, 2010
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Apricot Kernels Pose Risk of Cyanide Poisoning
Eating more than three small raw apricot kernels, or less than half of one large kernel, in a serving can exceed safe levels. Toddlers consuming even one small apricot kernel risk being over the safe level.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
A lncRNA Regulates Repair of DNA Breaks in Breast Cancer Cells
Findings give "new insight" into biology of tough-to-treat breast cancer.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!